Close Menu

Precision Oncology News: Breaking News

Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.

Under the agreement, AstraZeneca will be able to use ImaginAb's CD8 ImmunoPET technology in its clinical trials in North America and Europe.

Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.

The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year. 

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.

Tolero's investigational agent dubermatinib will be evaluated in AML patients who harbor a TP53 mutation and/or a complex karyotype.

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.

The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.

The Chinese drug evaluation agency has granted the investigational new drug clinical trial authorization to taletrectinib in NRTK- and ROS1-mutated cancer patients.

An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.

Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.

The drug, Amelie, will be for the second-line treatment of EGFR T790-mutated non-small cell lung cancer. 

The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.

The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.

In the upcoming clinical trial, the companies will evaluate the effects of IDEAYA's PKC inhibitor IDE196 and Pfizer's MEK inhibitor binimetinib.

The study will evaluate the effects of investigational drug IN10018 as a monotherapy and in combination with a MEK inhibitor.

Breast cancer patients with certain germline risk variants were more responsive to the chemotherapy combinations tested in a randomized trial.

A new study supports the development of BET inhibitors for MYCN-driven triple negative breast cancer as a single agent and in combination with a MEK inhibitor.

The trial evaluated the safety and preliminary activity of the single-agent therapy for FGFR2b-overexpressing gastric cancers.

The company's FGFR inhibitor infigratinib is being evaluated in solid tumors and urothelial cancer. 

The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.

The drug, JNJ-6372, is currently being studied in non-small cell lung cancer patients with EGFR exon 20 insertion mutations.

Pages